Free Trial
NASDAQ:PCRX

Pacira BioSciences (PCRX) Stock Price, News & Analysis

Pacira BioSciences logo
$22.90 -0.79 (-3.33%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$22.90 0.00 (-0.02%)
As of 07/11/2025 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pacira BioSciences Stock (NASDAQ:PCRX)

Key Stats

Today's Range
$22.75
$23.91
50-Day Range
$22.90
$26.98
52-Week Range
$11.16
$27.64
Volume
504,334 shs
Average Volume
901,916 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.44
Consensus Rating
Hold

Company Overview

Pacira BioSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

PCRX MarketRank™: 

Pacira BioSciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 403rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Pacira BioSciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Pacira BioSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Pacira BioSciences are expected to grow by 6.64% in the coming year, from $2.41 to $2.57 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pacira BioSciences is -10.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pacira BioSciences is -10.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pacira BioSciences has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pacira BioSciences' valuation and earnings.
  • Percentage of Shares Shorted

    12.92% of the float of Pacira BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Pacira BioSciences has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

  • Dividend Yield

    Pacira BioSciences does not currently pay a dividend.

  • Dividend Growth

    Pacira BioSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.92% of the float of Pacira BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Pacira BioSciences has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

  • News Sentiment

    Pacira BioSciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Pacira BioSciences this week, compared to 10 articles on an average week.
  • Search Interest

    2 people have searched for PCRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $146,199.00 in company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Pacira BioSciences is held by insiders.

  • Percentage Held by Institutions

    99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pacira BioSciences' insider trading history.
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Stock News Headlines

AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.
See More Headlines

PCRX Stock Analysis - Frequently Asked Questions

Pacira BioSciences' stock was trading at $18.84 at the start of the year. Since then, PCRX shares have increased by 21.5% and is now trading at $22.90.

Pacira BioSciences, Inc. (NASDAQ:PCRX) announced its quarterly earnings results on Tuesday, November, 2nd. The company reported $0.72 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.07. The firm's revenue for the quarter was up 8.7% compared to the same quarter last year.

Top institutional shareholders of Pacira BioSciences include Assenagon Asset Management S.A. (1.04%), Wealth Enhancement Advisory Services LLC (0.02%) and Farther Finance Advisors LLC (0.02%). Insiders that own company stock include David M Stack, Daryl Gaugler, Frank D Lee, Kristen Williams, Jonathan Slonin, Lauren Riker, Roy Winston, Charles A Reinhart III, Max Reinhardt, Kristen Marie Williams, Lauren Bullaro Riker, Anthony Molloy, Mark A Kronenfeld, Mark Froimson and Marcelo Bigal.
View institutional ownership trends
.

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
11/02/2021
Today
7/12/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PCRX
CIK
1396814
Employees
720
Year Founded
N/A

Price Target and Rating

High Price Target
$65.00
Low Price Target
$10.00
Potential Upside/Downside
+15.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
9.50
P/E Growth
N/A
Net Income
-$99.56 million
Net Margins
-14.78%
Pretax Margin
-9.69%
Return on Equity
13.78%
Return on Assets
7.00%

Debt

Debt-to-Equity Ratio
0.48
Current Ratio
2.41
Quick Ratio
1.99

Sales & Book Value

Annual Sales
$700.97 million
Price / Sales
1.51
Cash Flow
$4.17 per share
Price / Cash Flow
5.49
Book Value
$16.86 per share
Price / Book
1.36

Miscellaneous

Outstanding Shares
46,290,000
Free Float
43,328,000
Market Cap
$1.06 billion
Optionable
Optionable
Beta
0.48

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:PCRX) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners